within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09D_AngiotensinIiReceptorBlockersArbsCombinations.C09DX05_ValsartanAndNebivolol;
model ValsartanAndNebivolol 
   extends Pharmacolibrary.Drugs.ATC.C.C09DX05;

  annotation(Documentation(
    info ="<html><body><p>Valsartan and nebivolol is a fixed-dose antihypertensive combination containing an angiotensin II receptor blocker (valsartan) and a beta-1 selective adrenergic blocker (nebivolol). This combination is used for the treatment of essential hypertension in adults and may provide synergistic blood pressure-lowering effects. It is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>No published study reports pharmacokinetic model parameters specifically for the valsartan/nebivolol fixed combination. Estimates are provided below based on known PK data for monotherapy in healthy adults.</p><h4>References</h4><ol><li><p>Chen, CL, et al., &amp; Ghahramani, P (2015). A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State. <i>American journal of therapeutics</i> 22(5) e130–e140. DOI:<a href=&quot;https://doi.org/10.1097/MJT.0000000000000247&quot;>10.1097/MJT.0000000000000247</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25853236/&quot;>https://pubmed.ncbi.nlm.nih.gov/25853236</a></p></li><li><p>Selvan, PS, et al., &amp; Pal, TK (2007). Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 858(1-2) 143–150. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2007.08.016&quot;>10.1016/j.jchromb.2007.08.016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17884739/&quot;>https://pubmed.ncbi.nlm.nih.gov/17884739</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end ValsartanAndNebivolol;
